Evidence map›Paper›PMID 23891651›Full record

ArticlePeptides2013

Morphine treatment selectively regulates expression of rat pituitary POMC and the prohormone convertases PC1/3 and PC2.

Ying Nie, Monica G Ferrini, Yanjun Liu, Adrian Anghel, Enma V Paez Espinosa, Ronald C Stuart, Kabirullah Lutfy, Eduardo A Nillni, Theodore C Friedman

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Peptides, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ying Nie *Department of Radiation Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Monica G Ferrini *Division of Endocrinology, Department of Medicine, Charles R. Drew University of Medicine & Science-UCLA School of Medicine, Los Angeles, CA 90059, USA.
Yanjun Liu *Division of Endocrinology, Department of Medicine, Charles R. Drew University of Medicine & Science-UCLA School of Medicine, Los Angeles, CA 90059, USA.
Adrian AnghelDivision of Endocrinology, Department of Medicine, Charles R. Drew University of Medicine & Science-UCLA School of Medicine, Los Angeles, CA 90059, USA.
Enma V Paez EspinosaDivision of Endocrinology, Department of Medicine, Charles R. Drew University of Medicine & Science-UCLA School of Medicine, Los Angeles, CA 90059, USA.
Ronald C StuartDivision of Endocrinology, Department of Medicine, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island 02903, USA.
Kabirullah LutfyDivision of Endocrinology, Department of Medicine, Charles R. Drew University of Medicine & Science-UCLA School of Medicine, Los Angeles, CA 90059, USA.
Eduardo A NillniDivision of Endocrinology, Department of Medicine, The Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island 02903, USA.
Theodore C FriedmanDivision of Endocrinology, Department of Medicine, Charles R. Drew University of Medicine & Science-UCLA School of Medicine, Los Angeles, CA 90059, USA.
Charles R. Drew University of Medicine and Science · USBrown University · USCedars-Sinai Medical Center · US

Funding

Sustaining Faculty Development & Community EngagementS21MD000103 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CARLISLE, DAVID M · 2001 to 2015
$73.9M
Drew MIDARP (Infrastructure in Drug Abuse Research)R24DA017298 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2004 to 2018
$5.0M
The Role of H6PDH and 11beta-HSD1 in Type 2 Diabetes and ObesitySC1DK087655 · NIDDK · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI LIU, YANJUN · 2009 to 2013
$1.6M
Hypothalamic SIRT1 and Energy BalanceR01DK085916 · NIDDK · RHODE ISLAND HOSPITAL · PI NILLNI, EDUARDO A. · 2010 to 2013
$1.4M
Nitric Oxide/cGMP Modulation of Corporal Fibrosis Caused by NeuropraxiaSC1NS064611 · NINDS · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI FERRINI, MONICA GABRIELA · 2008 to 2012
$1.4M
Genes and Proteins Leading to AddictionR01DA014659 · NIDA · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI FRIEDMAN, THEODORE C · 2002 to 2006
$1.1M
THE OFQ/N/ORL-1 RECEPTOR SYSTEM &COCAINE SENSITIZATIONR01DA016682 · NIDA · WESTERN UNIVERSITY OF HEALTH SCIENCES · PI LUTFY, KABIRULLAH · 2004 to 2006
$513k
NIDA NIH HHS R01 DA014659NIDA NIH HHS R01 DA016682NIDA NIH HHS R01 DA14659NIDA NIH HHS R01 DA16682NIDA NIH HHS R24 DA017298NIDA NIH HHS R24DA017298NIDDK NIH HHS R01 DK085916NIDDK NIH HHS SC1 DK087655NIDDK NIH HHS SC1DK087655NIMHD NIH HHS S21 MD000103NINDS NIH HHS SC1 NS064611
6 · The paper itself

Abstract

The prohormone convertases, PC1/3 and PC2 are thought to be responsible for the activation of many prohormones through processing including the endogenous opioid peptides. We propose that maintenance of hormonal homeostasis can be achieved, in part, via alterations in levels of these enzymes that control the ratio of active hormone to prohormone. In order to test the hypothesis that exogenous opioids regulate the endogenous opioid system and the enzymes responsible for their biosynthesis, we studied the effect of short-term morphine or naltrexone treatment on pituitary PC1/3 and PC2 as well as on the level of pro-opiomelanocortin (POMC), the precursor gene for the biosynthesis of the endogenous opioid peptide, β-endorphin. Using ribonuclease protection assays, we observed that morphine down-regulated and naltrexone up-regulated rat pituitary PC1/3 and PC2 mRNA. Immunofluorescence and Western blot analysis confirmed that the protein levels changed in parallel with the changes in mRNA levels and were accompanied by changes in the levels of phosphorylated cyclic-AMP response element binding protein. We propose that the alterations of the prohormone processing system may be a compensatory mechanism in response to an exogenous opioid ligand whereby the organism tries to restore its homeostatic hormonal milieu following exposure to the opioid, possibly by regulating the levels of multiple endogenous opioid peptides and other neuropeptides in concert.

Indexed as

AnimalsCyclic AMP Response Element-Binding ProteinGene Expression RegulationMaleMorphineNaltrexoneNarcotic AntagonistsNarcoticsPituitary GlandPro-OpiomelanocortinProprotein Convertase 1Proprotein Convertase 2RatsRats, Sprague-DawleyRNA, MessengerCyclic AMP Response Element-Binding ProteinMorphineNaltrexoneNarcotic AntagonistsNarcoticsPro-OpiomelanocortinProprotein Convertase 1Proprotein Convertase 2RNA, MessengerDrug addictionEndorphinOpioidsPituitaryPost-translational processingProhormone convertase

Identifiers

PMID23891651
PMCPMC3787842
OpenAlexW2027512432

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.